← all events raw scan snapshot Apr 26, 2026 — prices as of scan date, not live 81 rows · screens, not recommendations ported fromresearch/classic/scans/2026-04-26-biotech-scan.md
XBI at 52-week highs while large-cap pharma weakens; DHR and IQV getting crushed (RSI 31-38); gene editing bifurcated — CRSP -15% this week vs NTLA strong-up; LEGN biotech moonshot +35% 30D.
Quick Snapshot Signal Reading Overall 🟡 Mixed — biotech ETFs (XBI/LABU) holding strong while pharma/medtech pulls back hard Key insight DHR RSI 31 with -25% 3M and death cross — life sciences tools entering capitulation; LLY down from $1,130 high, RSI 38; NKTR +147% 3M is the monster alert
Price Table Large-Cap Pharma Stock Price 7D 30D 3M RSI vs SMA20 Trend Status Action LLY $883.96 -4.34% -3.53% -16.68% 38.3 -4.0% down 🟡 Pullback 🔍 Watch GILD $130.40 -5.14% -5.68% -4.82% 30.9 -5.3% weak-down 🟢 Oversold 📈 Accumulate AMGN $344.55 -2.49% -2.65% -0.79% 42.8 -1.2% weak-down 🟡 Neutral 🔒 Hold BIIB $184.38 +0.82% -2.54% +6.5% 52.4 +2.0% weak-down 🟡 Neutral 🔒 Hold ABBV $198.71 -3.45% -3.29% -9.24% 35.2 -4.0% down 🟡 Weak 🔍 Watch REGN $746.46 -2.1% -1.38% -0.9% 45.2 -1.0% weak-down 🟡 Neutral 🔒 Hold VRTX $440.05 -0.56% -5.59% -2.11% 44.1 -1.6% weak-down 🟡 Neutral 🔒 Hold INCY $94.65 -3.54% +2.62% -7.73% 46.8 -0.7% weak-down 🟡 Neutral 🔒 Hold MRK — — — — — — — — — NVO $40.81 +4.1% +9.65% -32.12% 64.6 +11.4% weak-up 🟡 Dead-cat? 🔍 Watch
mRNA / Vaccines Stock Price 7D 30D 3M RSI vs SMA20 Trend Status Action MRNA $50.73 -8.2% -5.25% +5.71% 45.4 -2.0% weak-down 🟡 Neutral 🔍 Watch BNTX $105.46 +0.64% +18.8% -10.63% 61.2 +8.9% up 🟡 Bouncing 🔒 Hold
Gene Editing Stock Price 7D 30D 3M RSI vs SMA20 Trend Status Action CRSP $48.78 -15.44% +3.59% -10.74% 40.7 -6.7% strong-down 🟡 Weak 🔍 Watch BEAM $27.11 -13.09% +17.26% -12.41% 46.5 -1.1% strong-up 🟡 Pullback 🔍 Watch EDIT $2.91 -16.14% +25.43% +41.26% 50.2 -2.0% up 🟡 Volatile ⚠️ Speculative NTLA $14.94 -8.16% +11.66% +19.52% 63.5 +12.0% strong-up 🟢 Strong 📈 Accumulate
Life Sciences / Tools / Diagnostics Stock Price 7D 30D 3M RSI vs SMA20 Trend Status Action DHR $177.25 -9.09% -5.09% -24.96% 31.6 -7.0% strong-down 🟢 Approaching 🔍 Research TMO $514.23 +1.59% +9.41% -17.22% 58.9 +5.8% weak-up 🟡 Neutral 🔒 Hold ILMN $127.88 -4.42% +1.33% -16.42% 49.5 +0.4% strong-up 🟡 Neutral 🔍 Watch A $115.55 -4.58% +2.51% -14.62% 46.0 -0.9% strong-down 🟡 Weak 🔍 Watch IQV $162.28 -8.23% -2.03% -32.22% 38.6 -5.1% strong-down 🟡 Weak 🔍 Watch DXCM $61.57 -5.53% -7.88% -16.05% 39.9 -2.4% strong-down 🟡 Weak 🔍 Watch EXAS $104.91 +1.13% +1.02% +2.34% 75.4 +1.2% strong-up 🟠 Overbought ⚠️ Avoid MDT $83.32 -3.95% -4.43% -16.55% 36.5 -3.2% strong-down 🟡 Weak 🔍 Watch
Specialty Biotech Stock Price 7D 30D 3M RSI vs SMA20 Trend Status Action ALNY $305.54 -1.0% -7.05% -15.44% 40.9 -4.8% strong-down 🟡 Weak 🔍 Watch BMRN $53.18 -4.08% -4.34% -6.34% 37.0 -3.6% down 🟡 Weak 🔍 Watch IONS $73.27 -2.54% +0.78% -9.54% 42.6 -2.0% weak-down 🟡 Neutral 🔒 Hold ISRG $482.22 +2.6% +2.6% -8.81% 55.8 +4.4% weak-up 🟡 Neutral 🔒 Hold PTGX $105.44 +0.06% +8.98% +28.6% 59.8 +3.7% strong-up 🟢 Strong 🔒 Hold COGT $36.81 -0.67% +0.85% -2.77% 52.2 +1.1% strong-up 🟢 Strong 🔒 Hold KYMR $84.91 -2.88% +7.58% +19.49% 49.5 -1.2% strong-up 🟢 Strong 🔒 Hold NKTR $91.68 -8.59% +27.19% +146.58% 64.8 +12.6% strong-up 🟠 Extended ⚠️ Avoid LEGN $23.90 +3.37% +35.8% +26.05% 66.6 +18.0% weak-up 🟠 Extended 🔍 Watch RARE $25.18 +4.91% +15.4% +11.96% 68.3 +16.4% weak-up 🟡 Bouncing 🔍 Watch SRPT $21.79 -9.72% +30.79% -4.43% 56.5 +7.5% up 🟡 Volatile ⚠️ Caution DNA $7.87 -1.99% +6.93% -20.1% 55.4 +10.0% weak-up 🟡 Neutral ⚠️ Speculative RXRX $3.42 +3.13% +0.88% -29.48% 53.9 +6.5% strong-down 🟡 Bounce ⚠️ Speculative
Biotech ETFs Stock Price 7D 30D 3M RSI vs SMA20 Trend Status Action XBI $132.05 -0.34% +6.57% +4.12% 61.3 +5.4% strong-up 🟢 Strong 🔒 Hold IBB $169.78 -3.79% +2.43% -3.38% 47.0 -0.8% weak-down 🟡 Neutral 🔒 Hold IBBQ $29.34 -3.77% +3.09% -1.01% 48.7 -0.3% strong-up 🟡 Neutral 🔒 Hold LABU $186.29 -10.47% +20.26% +3.97% 52.5 +2.6% strong-up 🟡 Pullback 🔒 Hold
Tier Analysis RSI < 30 — Capitulation Territory None in extreme capitulation. GILD closest at RSI 30.9 — borderline oversold.
RSI 30–40 — Oversold / Strong Entry Zone Stock Price RSI 30D% Notes GILD $130.40 30.9 -5.68% Antiviral royalty machine, -17% from high, golden cross intact DHR $177.25 31.6 -5.09% Life sciences tools, -27% from high, -25% 3M; death cross — wait for flush ABBV $198.71 35.2 -3.29% Immunology/oncology, -19% from high; golden cross still holds MDT $83.32 36.5 -4.43% Medtech, -22% from high, death cross; slow-motion grind down BMRN $53.18 37.0 -4.34% Rare disease, -20% from high; cheap but downtrend LLY $883.96 38.3 -3.53% GLP-1 king, -22% from $1,134 high; golden cross intact — quality pullback IQV $162.28 38.6 -2.03% CRO/healthcare IT, -34% from high, -32% 3M; structural pressure DXCM $61.57 39.9 -7.88% CGM leader, -32% from high, death cross; competition risk
RSI 40+ — Neutral / Watch Stock Price RSI 30D% Notes ALNY $305.54 40.9 -7.05% RNA interference, -38% from high; quality but downtrend CRSP $48.78 40.7 +3.59% Gene editing, -38% from high; -15% this week, death cross NTLA $14.94 63.5 +11.66% CRISPR small-cap, strong-up, golden cross — speculative momentum LEGN $23.90 66.6 +35.8% Cell therapy, +35% 30D; -47% from high — dead-cat risk NKTR $91.68 64.8 +27.19% +147% 3M; parabolic move on news — chase risk
Entry Zones APPROACHING OVERSOLD (RSI 30-40) — Best Risk/Reward Stock Current Zone RSI 30D Action Notes GILD $130.40 <$130 30.9 -5.68% 📈 Accumulate Near 52-wk low relative support, golden cross, +30% 1Y compounder LLY $883.96 <$880 38.3 -3.53% 🔍 Watch GLP-1 secular leader; -22% from high; golden cross; quality pullback DHR $177.25 <$175 31.6 -5.09% 🔍 Research -25% 3M but death cross — watch for flush below $170 before entering ABBV $198.71 <$195 35.2 -3.29% 🔍 Watch Dividend growth + immunology; -19% from high; golden cross
Action Matrix Action Stocks Why 📈 ACCUMULATE GILD RSI 31, golden cross, -17% from high; antiviral royalty stream 🔒 HOLD AMGN, REGN, BIIB, VRTX, INCY, ISRG, IONS, PTGX, COGT, KYMR, NTLA Thesis intact, various stages of consolidation 🔒 HOLD XBI, IBB, IBBQ, LABU Biotech ETF exposure intact 🔒 HOLD BNTX +19% 30D bounce; RSI 61; hold stop 🔍 WATCH LLY, ABBV, NVO, CRSP, BEAM, DHR, IQV, MDT, DXCM Pullbacks in quality names — each needs individual catalyst check 🔍 RESEARCH DHR Death cross + -25% 3M = life sciences demand destruction? Or tariff-driven CRO pause? ⚠️ AVOID / CAUTION NKTR, EXAS, LEGN, SRPT, EDIT, DNA, RXRX Extended moves, parabolic, speculative, or broken thesis
What Changed vs 2026-04-10 Stock Apr 10 Apr 26 Move Note GILD $140.70 / RSI 50 $130.40 / RSI 31 -7.3% Entered oversold territory LLY $939.32 / RSI 47 $883.96 / RSI 38 -5.9% Continued decline, approaching oversold BIIB $173.72 / RSI 40 $184.38 / RSI 52 +6.1% Recovered from oversold back to neutral CRSP $50.17 / RSI 50 $48.78 / RSI 41 -2.8% But -15% this week, lost Apr 10 bounce NVO $37.51 / RSI 49 $40.81 / RSI 65 +8.8% Bouncing from lows — but still -50% from 52wk high BNTX $93.39 / RSI 51 $105.46 / RSI 61 +12.9% Strongest mRNA move — outperforming MRNA DHR Not in Apr 10 $177.25 / RSI 32 — New oversold alert — life sciences tools breaking down IQV Not in Apr 10 $162.28 / RSI 39 — New watch — CRO sector -32% 3M XBI Not in Apr 10 $132.05 / RSI 61 — ETF at 52-week high — speculative biotech outperforming large-cap NKTR Not in Apr 10 $91.68 / RSI 65 — Monster +147% 3M — late-stage alert
Key Discoveries Discovery Implication XBI near 52-week high while IBB weak Small/mid biotech outperforming large-cap pharma — speculative risk-on rotation Life sciences tools (DHR, IQV, A) all -15% to -32% 3M CRO/CDMO sector under structural pressure — tariff-driven research pause? GILD at RSI 31 with golden cross intact Rare setup: approaching oversold but golden cross = buyers still present NKTR +147% 3M on strong-up Classic parabolic — one clinical readout away from reversal
Open Questions
Is DHR /IQV selling tariff-driven (China lab slowdown) or structural (post-COVID CRO glut)?
NVO bouncing at $40 — dead-cat rally or genuine bottom? Watch RSI trend next 2 weeks.CRSP -15% this week — specific catalyst or sector rotation out of gene editing?
No direct external sources are attached to this read.